After the markets closed on Tuesday, Xoma put out the word that its main pipeline asset, gevokizumab (Xoma 052) flunked a Phase II program for erosive osteoarthritis of the hand, ending any shot it had at a broad pivotal study in that indication.

…read more

Source: Xoma drug fails to beat out a placebo in PhII osteoarthritis study


0 No comments